{{Drugbox
| verifiedrevid = 460022886
| IUPAC_name = 8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-<br>ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-<br>azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid
| image = Cefdinir.svg
<!--Clinical data-->
| tradename = Cefzon, Omnicef
| Drugs.com = {{drugs.com|monograph|cefdinir}}
| MedlinePlus = a698001
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Rx only
| legal_status =  
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 16% to 21% (dose-dependent)
| protein_bound = 60% to 70%
| metabolism = Negligible
| elimination_half-life = 1.7 ± 0.6 hours
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 91832-40-5
| ATC_prefix = J01
| ATC_suffix = DD15
| ATC_supplemental =  
| PubChem = 6915944
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00535
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5291705
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CI0FAO63WC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00917
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3485
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 927
<!--Chemical data-->
| C=14 | H=13 | N=5 | O=5 | S=2
| molecular_weight = 395.416 g/mol
| smiles = O=C2N1/C(=C(/C=C)CS[C@@H]1[C@@H]2NC(=O)C(=N\O)/c3nc(sc3)N)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RTXOFQZKPXMALH-GHXIOONMSA-N
}}
'''Cefdinir''' is a third-generation oral [[cephalosporin]] [[antibiotic]] sold under the brand names Cefzon and Omnicef.

As of 2008, cefdinir, as Omnicef, was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.<ref>{{cite web|url=http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/192009/597086/article.pdf |title="2008 Top 200 generic drugs by retail dollars" |deadurl=yes |archiveurl=https://web.archive.org/web/20120112121937/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf |archivedate=2012-01-12 |df= }}&nbsp;{{small|(399.4&nbsp;KB)}}. ''Drug Topics'' (May 26, 2009). Retrieved on July 24, 2009.</ref>  [[Cefdinir]] is structurally similar to [[cefixime]].

It was discovered by Fujisawa Pharmaceutical Co., Ltd.  (now [[Astellas]]) and introduced in 1991 under the brand name Cefzon.<ref>{{cite web|url=http://www.astellas.com/en/corporate/news/detail/astellas-filed-lawsuit-against.html|title=2005 News Releases - Astellas Pharma Inc.|work=astellas.com}}</ref><ref>{{Cite journal|url=http://wenku.baidu.com/view/a2ef6330b90d6c85ec3ac6fa.html|doi=10.1021/op0601060|title=Polymorphisms and Patent, Market, and Legal Battles:  Cefdinir Case Study|journal=Organic Process Research & Development|volume=11|pages=64|year=2007|last1=Cabri|first1=Walter|last2=Ghetti|first2=Paolo|last3=Pozzi|first3=Giovanni|last4=Alpegiani|first4=Marco}}</ref> Warner-Lambert licensed this cephalosporin for marketing in US from Fujisawa.<ref>{{cite web|url=http://www.elsevierbi.com/publications/the-pink-sheet/52/005/comprecin-has-excellent-chance-to-reach-us-market-this-year-dupont-prophenytoin-crosslicense-deal?p=1|title=Document|work=elsevierbi.com}}</ref> Abbott obtained U.S. marketing rights to Omnicef (cefdinir) in December 1998 through an agreement with Warner-Lambert Company.<ref>{{cite web|url=http://www.globenewswire.com/newsarchive/mrx/pages/news_releases.html?d=94045|title=Medicis.com - Medicis Pharmaceutical Corporation|work=globenewswire.com}}</ref> It was approved by FDA on Dec 4, 1997.<ref>{{cite web|url=http://www.drugs.com/mtm/cefdinir.html|title=Cefdinir medical facts from Drugs.com|work=drugs.com}}</ref> It is available in US as Omnicef by [[Abbott Laboratories]] and in India as Cednir by Abbott, Kefnir by Glenmark, Cefdair by Xalra Pharma and Cefdiel by [[Ranbaxy]].

==Mechanism of action==
{{main|Cephalosporin}}

==Indications==
Therapeutic uses of cefdinir include [[otitis media]], [[soft tissue]] infections, and [[respiratory tract]] infections, including sinusitis, strep throat (note: no documented resistance of Group A Streptococcus to penicillin has ever been reported, and penicillin or amoxicillin is preferred except in penicillin allergic patients), [[community-acquired pneumonia]], and acute exacerbations of [[bronchitis]].

==Susceptible organisms==
Cefdinir is a [[bacteriocide|bacteriocidal]] antibiotic of the cephalosporin class of antibiotics. It can be used to treat infections caused by several [[Gram-negative]] and [[Gram-positive]] bacteria. 

==Spectrum of bacterial susceptibility and resistance==
Cefdinir is a broad-spectrum antibiotic and has been used to treat infections of the respiratory tract including pneumonia, sinusitis, and bronchitis. The following represents MIC susceptibility data for a few medically significant microorganisms.<ref>{{cite web |url=http://www.toku-e.com/Assets/MIC/Cefdinir.pdf |title=Susceptibility and Minimum Inhibitory Concentration (MIC) Data |date=October 14, 2015 |accessdate= 1 October 2015}}</ref>
* ''Haemophilus influenzae'': 0.05 - 4 μg/ml
* ''Streptococcus pneumoniae'': 0.006 - 64 μg/ml
* ''Streptococcus pyogenes'': ≤0.004 - 2 μg/ml

==Side effects==

Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain."<ref>{{cite web | title = Omnicef capsules Patient Information | publisher = [[Abbott Laboratories]] | url = http://www.rxabbott.com/pdf/omnicef_capsules_patient_friendly.pdf |date=February 2004 | accessdate = 2006-11-24 |archiveurl = https://web.archive.org/web/20061118132152/http://www.rxabbott.com/pdf/omnicef_capsules_patient_friendly.pdf|archivedate = 2006-11-18}}</ref>

It is also one of the medications that can cause [[toxic epidermal necrolysis]] or [[Stevens-Johnson Syndrome]].<ref>{{cite web | title = Omnicef manufacturer's packet insert | publisher = [[FDA]] | url = http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf | accessdate = 2016-12-11}}</ref>

==Available forms==
Cefdinir is administered orally. It is available as capsules and a suspension. Dosage, schedule, and duration of therapy varies according to the type of infection.

=="Blood" in the stool==
The pediatric version of cefdinir can bind to iron in the digestive tract; in rare cases, this causes a rust or red discoloration of the stool.   Blood typically appears dark brown or black in stool, and testing may confirm which is present.  If the reddish stool is accompanied by abdominal pain, weight loss, diarrhea, etc., a ''[[Clostridium difficile colitis|Clostridium difficile]]'' infection caused by the antibiotic could be signified.

==Synthesis==
[[File:Cefdinir synthesis.svg|thumb|center|700px|Cefdinir synthesis:<ref>T. Takaya et al., {{Cite patent|BE|897864}}; eidem, {{US patent|4559334}} (1984, 1985 both to Fujisawa Pharmaceuticals).</ref><ref>{{cite journal|pmid=3255303|year=1988|author1=Inamoto|first1=Y|title=FK 482, a new orally active cephalosporin synthesis and biological properties|journal=The Journal of antibiotics|volume=41|issue=6|pages=828–30|last2=Chiba|first2=T|last3=Kamimura|first3=T|last4=Takaya|first4=T|doi=10.7164/antibiotics.41.828}}</ref><ref>{{cite journal|pmid=3198494|year=1988|author1=Kamachi|first1=H|title=Synthesis and biological activity of a new cephalosporin, BMY-28232 and its prodrug-type esters for oral use|journal=The Journal of antibiotics|volume=41|issue=11|pages=1602–16|last2=Narita|first2=Y|last3=Okita|first3=T|last4=Abe|first4=Y|last5=Iimura|first5=S|last6=Tomatsu|first6=K|last7=Yamasaki|first7=T|last8=Okumura|first8=J|last9=Naito|first9=T|last10=Oki|first10=T|doi=10.7164/antibiotics.41.1602}}</ref> Improved prepn:<ref>{{cite journal|pmid=12767379|year=2003|author1=González|first1=M|title=An alternative procedure for preparation of cefdinir|journal=Il Farmaco|volume=58|issue=6|pages=409–18|last2=Rodríguez|first2=Z|last3=Tolón|first3=B|last4=Rodríguez|first4=J. C.|last5=Velez|first5=H|last6=Valdés|first6=B|last7=López|first7=M. A.|last8=Fini|first8=A|doi=10.1016/S0014-827X(03)00063-6}}</ref>]]
Acylation of the primary amine '''1''' with 4-bromo-3-oxobutanoyl bromide ('''2''') leads to the amide ('''3'''). The active [[methylene group]] in that product is then nitrosated with [[sodium nitrite]]; the initial product spontaneously tautomerizes to afford the [[oxime]] ('''4'''). The bromoketone array in that intermediate constitutes a classical starting function for construction of [[thiazole]]s. Reaction of '''4''' with [[thiourea]] thus leads to formation of an aminothiazole moiety. Thus there is obtained the antibiotic cefdinir ('''5''').

==References==
{{Reflist|30em}}

==External links==
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a698001.html Medline Plus: Cefdinir]

{{Cell wall disruptive antibiotics}}

[[Category:Thiazoles]]
[[Category:Astellas Pharma]]
[[Category:Vinyl compounds]]